Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer

BACKGROUND: Currently available third- or later-line therapy for metastatic colorectal cancer (mCRC) is limited in its efficacy, with a weak survival benefit in patients who progressed after two or more lines of standard therapy. Our retrospective study aimed to explore the value of bevacizumab plus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Yang, Qiong, Yin, Chenxi, Liao, Fangxin, Huang, Yuanyuan, He, Wenzhuo, Jiang, Chang, Guo, Guifang, Zhang, Bei, Xia, Liangping
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562721/
https://ncbi.nlm.nih.gov/pubmed/26366095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S88679
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados